Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takehiro Tanaka

Showing results (311-320 of 312) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 312 results.
Japanese Journal of Clinical Oncology|July 9, 2026
Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world studyIbuki Tsuru, Satoru Taguchi, Ryo Tanaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 32

Showing results (311-320 of 312) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 312 results.
Japanese Journal of Clinical Oncology|July 9, 2026
Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world studyIbuki Tsuru, Satoru Taguchi, Ryo Tanaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 32